- Conditions
- Glioma
- Interventions
- Rhenium Liposome Treatment
- Drug
- Lead sponsor
- Cerenome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 4
- States / cities
- Manhasset, New York • Columbus, Ohio • Dallas, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 708
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain Cancer, MALIGNANT GLIOMA, Glioblastoma, Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Anaplastic Oligo-astrocytoma (AOA), Anaplastic Mixed Gliomas, Malignant Glioma NOS
- Interventions
- Bevacizumab & Stereotactic Radiotherapy
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 5
- States / cities
- San Francisco, California • Basking Ridge, New Jersey • Commack, New York + 2 more
- Conditions
- Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- ixabepilone, pharmacological study, Anticonvulsant
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 2 more
- Conditions
- Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
- Interventions
- Cancer vaccine plus immune adjuvant
- Biological
- Lead sponsor
- TVAX Biomedical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Glioblastoma Multiforme
- Interventions
- ICT-121 DC vaccine
- Biological
- Lead sponsor
- Precision Life Sciences Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 3 more
- Conditions
- Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Giant Cell Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Glioblastoma, Small Cell Glioblastoma
- Interventions
- autologous dendritic cells pulsed with tumor lysate antigen Vaccine, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Gliosarcoma, Brain Neoplasms, Central Nervous System Neoplasms
- Interventions
- topotecan, pazopanib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Glioblastoma
- Interventions
- Pembrolizumab, Optune GIO®, NeuroBlate®
- Drug · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- karenitecin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult
- Interventions
- Pamiparib, Olaparib, Radiation therapy, Temozolomide
- Drug · Radiation
- Lead sponsor
- Nader Sanai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Recurrent or Progressive Malignant Glioma
- Interventions
- ANG1005
- Drug
- Lead sponsor
- Angiochem Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more
- Conditions
- Glioblastoma, Recurrent Glioblastoma
- Interventions
- Avutometinib, Biospecimen Collection, Defactinib
- Drug · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- psychosocial assessment and care
- Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2005
- U.S. locations
- 26
- States / cities
- Sacramento, California • Gainesville, Florida • Miami, Florida + 23 more
- Conditions
- Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 51
- States / cities
- Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Interventions
- Conventional Surgery, Laboratory Biomarker Analysis, Sorafenib Tosylate, Temsirolimus
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 190
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Hartford, Connecticut + 118 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- bevacizumab, dasatinib, placebo
- Biological · Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 305
- States / cities
- Scottsdale, Arizona • La Jolla, California • Pismo Beach, California + 179 more
- Conditions
- Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, PNET, Cerebral Primitive Neuroectodermal Tumor, Embryonal Tumor
- Interventions
- G207
- Biological
- Lead sponsor
- Gregory K. Friedman, MD
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Columbus, Ohio
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Interventions
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Drug · Procedure
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
- Conditions
- High-grade Glioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 4 Years to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2045
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Recurrent Glioblastoma
- Interventions
- CART-EGFR-IL13Ra2 T cells
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- High Grade Glioma, Anaplastic Astrocytoma
- Interventions
- DB107-RRV, DB107-FC
- Drug
- Lead sponsor
- Ashish Shah
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Imatinib Mesylate & Hydroxyurea
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma
- Interventions
- Paxalisib, Metformin, Ketogenic Diet
- Drug · Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York